Literature DB >> 6186500

Intrathecal opioids block a spinal action of substance P in mice: functional importance of both mu- and delta-receptors.

J L Hylden, G L Wilcox.   

Abstract

Inhibition of intrathecal substance P-elicited behavior by mu-, delta- and kappa-opioids was compared. In both the substance P behavioral test and the tail flick antinociceptive test, intrathecal [D-Ala2, Met5]enkephalinamide and [D-Ala2, D-Leu5]enkephalin (DADL) were equipotent, morphine and ethylketazocine were less potent, but nalorphine was inactive. A long-lasting, highly selective, mu-receptor antagonist, beta-funaltrexamine, blocked the inhibition of substance P behaviors by both morphine and ethylketazocine, but did not block the effect of DADL. These results suggest that spinal postsynaptic modulation of nociception is mediated by both delta-type and mu-type opioid agonists.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6186500     DOI: 10.1016/0014-2999(82)90403-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Peripheral mechanisms of pain and analgesia.

Authors:  Christoph Stein; J David Clark; Uhtaek Oh; Michael R Vasko; George L Wilcox; Aaron C Overland; Todd W Vanderah; Robert H Spencer
Journal:  Brain Res Rev       Date:  2008-12-31

2.  Protein kinase C mediates the synergistic interaction between agonists acting at alpha2-adrenergic and delta-opioid receptors in spinal cord.

Authors:  Aaron C Overland; Kelley F Kitto; Anne-Julie Chabot-Doré; Patrick E Rothwell; Carolyn A Fairbanks; Laura S Stone; George L Wilcox
Journal:  J Neurosci       Date:  2009-10-21       Impact factor: 6.167

3.  Substance P markedly potentiates the antinociceptive effects of morphine sulfate administered at the spinal level.

Authors:  R M Kream; T Kato; H Shimonaka; J E Marchand; W H Wurm
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

Review 4.  Analgesic synergy between opioid and α2 -adrenoceptors.

Authors:  A-J Chabot-Doré; D J Schuster; L S Stone; G L Wilcox
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 5.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

6.  The effects of substance P analogues on the scratching, biting and licking response induced by intrathecal injection of N-methyl-D-aspartate in mice.

Authors:  T Sakurada; Y Manome; K Tan-No; S Sakurada; K Kisara
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

7.  Naloxone-reversible effect of spantide on the spinally mediated behavioural response induced by neurokinin-2 and -3 receptor agonists.

Authors:  T Sakurada; Y Manome; K Katsumata; H Uchiumi; K Tan-No; S Sakurada; K Kisara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

8.  Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.

Authors:  T M Largent-Milnes; S W Brookshire; D P Skinner; K E Hanlon; D Giuvelis; T Yamamoto; P Davis; C R Campos; P Nair; S Deekonda; E J Bilsky; F Porreca; V J Hruby; T W Vanderah
Journal:  J Pharmacol Exp Ther       Date:  2013-07-16       Impact factor: 4.030

9.  Transient allodynia pain models in mice for early assessment of analgesic activity.

Authors:  D W Gil; C V Cheevers; J E Donello
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

10.  Behavioural effects of intrathecally injected tachykinins in rats with peripheral nerve transection.

Authors:  H Kuwahara; T Sakurada; S Sakurada; A Yonezawa; R Ando; K Kisara; F Osakada; E Munekata
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-12       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.